Korsana Biosciences, Inc. (KRSA)
38.96
+3.51
(+9.90%)
USD |
NASDAQ |
Nov 20, 10:20
Korsana Biosciences Cash from Operations (Quarterly) : -46.83M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -46.83M |
| June 30, 2026 | -1.432M |
| March 31, 2026 | -1.176M |
| December 31, 2025 | -1.579M |
| September 30, 2025 | -10.33M |
| June 30, 2025 | -0.503M |
| March 31, 2025 | -0.968M |
| December 31, 2024 | 0.36M |
| September 30, 2024 | -1.716M |
| June 30, 2024 | -1.106M |
| March 31, 2024 | -1.871M |
| December 31, 2023 | -1.541M |
| September 30, 2023 | -6.935M |
| June 30, 2023 | -6.555M |
| March 31, 2023 | -6.214M |
| December 31, 2022 | -7.043M |
| September 30, 2022 | -9.915M |
| June 30, 2022 | -10.82M |
| Date | Value |
|---|---|
| March 31, 2022 | -12.84M |
| December 31, 2021 | -8.63M |
| September 30, 2021 | -7.923M |
| June 30, 2021 | -5.509M |
| March 31, 2021 | -14.46M |
| December 31, 2020 | -14.04M |
| September 30, 2020 | -15.05M |
| June 30, 2020 | -14.22M |
| March 31, 2020 | -29.18M |
| December 31, 2019 | -22.16M |
| September 30, 2019 | -23.81M |
| June 30, 2019 | -21.97M |
| March 31, 2019 | -34.27M |
| December 31, 2018 | -23.15M |
| September 30, 2018 | -25.30M |
| June 30, 2018 | -22.62M |
| March 31, 2018 | -26.43M |
| December 31, 2017 | -25.79M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Q32 Bio, Inc. | -4.418M |
| IRulya Therapeutics, Inc. | -9.84M |
| Climb Bio, Inc. | -12.00M |
| PepGen Inc. | -13.18M |
| Bridgebio Oncology Therapeutics, Inc. | -28.36M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.231M |
| Cash from Financing (Quarterly) | 351.10M |
| Free Cash Flow | -51.31M |
| Free Cash Flow Per Share (Quarterly) | -3.479 |
| Free Cash Flow to Equity (Quarterly) | -48.33M |
| Free Cash Flow to Firm (Quarterly) | -47.06M |
| Free Cash Flow Yield | -2.89% |